At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of a Probiotic Formulation (Lacticaseibacillus Rhamnosus - Limosilactobacillus Fermentum) on Gastrointestinal Symptoms in Adults With Lactose Intolerance and Methanogenic Intestinal Overgrowth
In Brief
A clinical study evaluating Probiotic formulation and Maltodextrin (Placebo) for Lactose Intolerance. Completed, enrolled 22 participants across 1 site.
Detailed Summary
Introduction: Lactose intolerance (LI) is characterized by specific gastrointestinal symptoms following the consumption of dairy products and lactose-containing foods, symptoms that may also be experienced by individuals with intestinal methanogenic overgrowth (IMO). However, such clinical manifestations may be modulated by the use of probiotics; the aim of this study was to analyze the preliminary efficacy of a probiotic formulation on gastrointestinal symptoms in adults with LI and IMO. Materials and Methods: A randomized, double-blind, placebo-controlled pilot study was conducted with 22 adults who tested positive on a hydrogen breath test (HBT); they were assigned to intervention or placebo groups based on their diagnosis. Accordingly, they completed a Questionnaire on symptoms of Lactose Intolerance (QSLT) and underwent successive nutritional assessments.
Study Details
Timeline
Arms & Interventions
Participants who received the capsules containing the two probiotic strains
Participants who received the capsules without the probiotic strains
Interventions
The individuals had to take one capsule daily containing the bi-strain probiotic formulation (Lacticaseibacillus rhamnosus L-134 and Limosilactobacillus fermentum L-33) for 12 weeks.
The individuals had to take one capsule daily containing maltodextrin for 12 weeks.